According to Eunice Kennedy Shriver National Institute of Child Health and Human Development, Pre-eclampsia (PE) is a disorder of pregnancy characterized by the onset of high blood pressure (>140/90 mmHg) and often a significant amount of protein in the urine. When it arises, the condition begins at or after 20 weeks of pregnancy.
The cause of Preeclampsia is unknown. However, experts believed that it is due to abnormal placentation. Researchers are investigating many factors that could contribute to the development and progression of PE such as genetic factors, maternal immunology, and autoimmune disorders, nutritional factors, environmental exposure, and cardiovascular and inflammatory changes. The complications of Preeclampsia may include fetal growth restriction, preterm birth, placental abruption, HELLP syndrome, eclampsia, cardiovascular disease, or organ damage (kidneys, liver, lung, heart, or eyes, and may cause a stroke or brain injury).
Currently, no specific strategies are established to prevent Preeclampsia. However, in certain cases, the risk of PE can be reduced by using low-dose aspirin and calcium supplement.
Get FREE sample copy at:
The Preeclampsia market report also covers emerging drugs, current treatment practices, Preeclampsia market share of the individual therapies, current and forecasted Preeclampsia Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Preeclampsia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Preeclampsia Market Key Facts
As per Eunice Kennedy Shriver National Institute of Child Health and Human Development, certain researchers and health care providers believe that in the US, Preeclampsia affects about 3.4% of pregnancies.
As per the Centers for Disease Control and Prevention, Preeclampsia affects 1 in 25 pregnancies in the US.
According to the National Health Service, mild preeclampsia affects up to 6% of pregnancies, and severe cases develop in about 1–2% of pregnancies.
According to the article by Weissgerber et al., titled “Preeclampsia and diabetes,” in developed countries, Preeclampsia affects 2–7% of pregnancies in non-diabetic women.
In Japan, the analysis of 1,300 pregnancies shows that a total of 30 women developed Preeclampsia, corresponding to an incidence of 2.31%.
Key Benefits of Preeclampsia Market Report
Preeclampsia market report provides an in-depth analysis of Preeclampsia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Preeclampsia market report will help in developing business strategies by understanding the Preeclampsia Market trends & developments, key players and future market competition that will shape and drive the Preeclampsia market in the upcoming years.
The Preeclampsia market report covers Preeclampsia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Preeclampsia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The key drivers for the Preeclampsia market is an increase in the risk factors of Preeclampsia such as obesity, diabetes, hypertension, and an increasing incidence of Preeclampsia. These factors along with the expected launch of emerging therapies will boost the Preeclampsia market in the forecasted period.
The Preeclampsia market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Preeclampsia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Preeclampsia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The Preeclampsia epidemiology section covers insights about historical and current Preeclampsia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Preeclampsia Drugs Uptake and Key Market Players
The Preeclampsia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Preeclampsia market or expected to get launched in the market during the study period. The analysis covers Preeclampsia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key companies in the Preeclampsia market include:
Kyowa Kirin Co., Ltd
VG Life Science
APP Pharmaceuticals (Fresenius Kabi USA)
And many others.
Preeclampsia Therapies Covered:
AMAG-423 (digoxin immune fab)
Table of Content
1. Key Insights
2. Executive Summary
3. Preeclampsia Competitive Intelligence Analysis
4. Preeclampsia Market Overview at a Glance
5. Preeclampsia Disease Background and Overview
6. Preeclampsia Patient Journey
7. Preeclampsia Epidemiology and Patient Population
8. Preeclampsia Treatment Algorithm, Current Treatment, and Medical Practices
9. Preeclampsia Unmet Needs
10. Key Endpoints of Preeclampsia Treatment
11. Preeclampsia Marketed Products
12. Preeclampsia Emerging Therapies
13. Preeclampsia Seven Major Market Analysis
14. Attribute Analysis
15. Preeclampsia Market Outlook (7 major markets)
16. Preeclampsia Access and Reimbursement Overview
17. KOL Views on the Preeclampsia Market.
18. Preeclampsia Market Drivers
19. Preeclampsia Market Barriers
21. DelveInsight Capabilities
Amebiasis Market Analysis
Amebiasis Market Insights, Epidemiology, and Market Forecast 2030 report deliver an in-depth understanding of the Amebiasis historical and forecasted epidemiology as well as the Amebiasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Endometrial Cancer Market Forecast
Endometrial Cancer Market Insights, Epidemiology, and Market Forecast 2030 report deliver an in-depth understanding of the Endometrial Cancer historical and forecasted epidemiology as well as the Endometrial Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States